Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RTN 001

Next Previous
Drug Profile

RTN 001

Alternative Names: RTN-001

Latest Information Update: 14 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sanofi
  • Developer Retension Pharmaceuticals
  • Class Antihypertensives; Small molecules
  • Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hypertension

Most Recent Events

  • 03 Sep 2025 Retension Pharmaceuticals plans to initiate a phase IIb trial for Hypertension in USA (PO) (NCT07142356)
  • 06 Aug 2025 Retension Pharmaceuticals has patent protection for RTN 001 in USA
  • 26 Aug 2024 Retension Pharmaceuticals plans a phase II trial for Hypertension (Treatment-experienced) (Retension Pharmaceuticals pipeline, August 2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top